Prednisone treatment (DrugBank: Prednisone)
47 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
11 | 重症筋無力症 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
14 | 慢性炎症性脱髄性多発神経炎/多巣性運動ニューロパチー | 0 |
19 | ライソゾーム病 | 0 |
26 | HTLV-1関連脊髄症 | 0 |
35 | 天疱瘡 | 0 |
40 | 高安動脈炎 | 0 |
41 | 巨細胞性動脈炎 | 2 |
42 | 結節性多発動脈炎 | 0 |
43 | 顕微鏡的多発血管炎 | 0 |
44 | 多発血管炎性肉芽腫症 | 0 |
45 | 好酸球性多発血管炎性肉芽腫症 | 0 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
51 | 全身性強皮症 | 0 |
53 | シェーグレン症候群 | 0 |
61 | 自己免疫性溶血性貧血 | 0 |
63 | 特発性血小板減少性紫斑病 | 0 |
64 | 血栓性血小板減少性紫斑病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
66 | IgA腎症 | 0 |
81 | 先天性副腎皮質酵素欠損症 | 0 |
84 | サルコイドーシス | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
93 | 原発性胆汁性胆管炎[原発性胆汁性肝硬変 (~2017.3)] | 0 |
95 | 自己免疫性肝炎 | 0 |
96 | クローン病 | 0 |
97 | 潰瘍性大腸炎 | 0 |
113 | 筋ジストロフィー | 0 |
127 | 前頭側頭葉変性症 | 0 |
162 | 類天疱瘡(後天性表皮水疱症を含む。) | 0 |
164 | 眼皮膚白皮症 | 0 |
222 | 一次性ネフローゼ症候群 | 3 |
224 | 紫斑病性腎炎 | 0 |
228 | 閉塞性細気管支炎 | 0 |
251 | 尿素サイクル異常症 | 0 |
283 | 後天性赤芽球癆 | 0 |
284 | ダイアモンド・ブラックファン貧血 | 0 |
285 | ファンコニ貧血 | 0 |
288 | 自己免疫性後天性凝固因子欠乏症[自己免疫性出血病XIII (~2017.3)] | 0 |
299 | 嚢胞性線維症 | 0 |
300 | IgG4関連疾患 | 0 |
331 | 特発性多中心性キャッスルマン病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03892785 (ClinicalTrials.gov) | January 27, 2020 | 26/3/2019 | MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial | Giant Cell Arteritis | Drug: Prednisone treatment;Drug: Tocilizumab treatment;Drug: Methotrexate treatment;Other: Questionnaires;Biological: Blood samples | Centre Hospitalier Universitaire Dijon | NULL | Recruiting | 50 Years | N/A | All | 200 | Phase 3 | France |
2 | NCT03711448 (ClinicalTrials.gov) | January 7, 2019 | 15/10/2018 | Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis | Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis | Patients Relapsing Refractory Giant Cell Arteritis | Drug: prednisone treatment;Drug: prednisone and ustekinumab treatment;Other: questionnaires;Biological: Blood samples | Centre Hospitalier Universitaire Dijon | NULL | Recruiting | 50 Years | N/A | All | 38 | Phase 2 | France |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | ChiCTR2000037014 | 2020-10-01 | 2020-08-26 | The predictive value of gut permeability in children with steroid dependent nephrotic syndrome | The predictive value of gut permeability in children with steroid dependent nephrotic syndrome | Primary nephrotic syndrome | Steroid sensitive nephrotic syndrome group (SSNS group):Prednisone treatment recommended by the guidelines;Steroid dependent nephrotic syndrome group (SDNS group):Prednisone treatment recommended by the guidelines; | Shanghai Children's Hospital | NULL | Pending | Both | Steroid sensitive nephrotic syndrome group (SSNS group):40;Steroid dependent nephrotic syndrome group (SDNS group):30; | China | |||
2 | ChiCTR-OPN-17012789 | 2006-06-01 | 2017-09-25 | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria | focal segmental glomerulosclerosis | study group:prednisone treatment;control group:ACEI/ARB; | Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine | NULL | Completed | 17 | 80 | Both | study group:52;control group:50; | China | |
3 | NCT00362531 (ClinicalTrials.gov) | November 2004 | 9/8/2006 | Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Phase 3 Study of Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome | Idiopathic Membranous Nephropathy;Nephrotic Syndrome | Drug: tacrolimus combined with prednisone | Peking University | NULL | Completed | 18 Years | 70 Years | Both | Phase 2;Phase 3 | NULL |